Janel L Kopp1, Claire L Dubois2, David F Schaeffer3, Atefeh Samani4, Farnaz Taghizadeh4, Robert W Cowan5, Andrew D Rhim5, Bangyan L Stiles6, Mark Valasek7, Maike Sander8. 1. Departments of Pediatrics and Cellular and Molecular Medicine, University of California-San Diego, La Jolla, California; Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, British Columbia, Canada. 2. Departments of Pediatrics and Cellular and Molecular Medicine, University of California-San Diego, La Jolla, California. 3. Department of Pathology and Laboratory and Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 4. Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, British Columbia, Canada. 5. Ahmed Center for Pancreatic Cancer Research and Department of Gastroenterology, Hepatology and Nutrition, University of Texas M.D. Anderson Cancer Center, Houston, Texas. 6. Department of Pharmaceutical Sciences, School of Pharmacy, Keck School of Medicine, University of Southern California, and the Norris Comprehensive Cancer Center, Los Angeles, California. 7. Department of Pathology, University of California-San Diego, La Jolla, California. 8. Departments of Pediatrics and Cellular and Molecular Medicine, University of California-San Diego, La Jolla, California. Electronic address: masander@ucsd.edu.
Abstract
BACKGROUND & AIMS: Intraductal papillary mucinous neoplasias (IPMNs) are precancerous cystic lesions that can develop into pancreatic ductal adenocarcinomas (PDACs). These large macroscopic lesions are frequently detected during medical imaging, but it is unclear how they form or progress to PDAC. We aimed to identify cells that form IPMNs and mutations that promote IPMN development and progression. METHODS: We generated mice with disruption of Pten specifically in ductal cells (Sox9CreERT2;Ptenflox/flox;R26RYFP or PtenΔDuct/ΔDuct mice) and used PtenΔDuct/+ and Pten+/+ mice as controls. We also generated KrasG12D;PtenΔDuct/ΔDuct and KrasG12D;PtenΔDuct/+ mice. Pancreata were collected when mice were 28 weeks to 14.5 months old and analyzed by histology, immunohistochemistry, and electron microscopy. We performed multiplexed droplet digital polymerase chain reaction to detect spontaneous Kras mutations in PtenΔDuct/ΔDuct mice and study the effects of Ras pathway activation on initiation and progression of IPMNs. We obtained 2 pancreatic sections from a patient with an invasive pancreatobiliary IPMN and analyzed the regions with and without the invasive IPMN (control tissue) by immunohistochemistry. RESULTS: Mice with ductal cell-specific disruption of Pten but not control mice developed sporadic, macroscopic, intraductal papillary lesions with histologic and molecular features of human IPMNs. PtenΔDuct/ΔDuct mice developed IPMNs of several subtypes. In PtenΔDuct/ΔDuct mice, 31.5% of IPMNs became invasive; invasion was associated with spontaneous mutations in Kras. KrasG12D;PtenΔDuct/ΔDuct mice all developed invasive IPMNs within 1 month. In KrasG12D;PtenΔDuct/+ mice, 70% developed IPMN, predominately of the pancreatobiliary subtype, and 63.3% developed PDAC. In all models, IPMNs and PDAC expressed the duct-specific lineage tracing marker yellow fluorescent protein. In immunohistochemical analyses, we found that the invasive human pancreatobiliary IPMN tissue had lower levels of PTEN and increased levels of phosphorylated (activated) ERK compared with healthy pancreatic tissue. CONCLUSIONS: In analyses of mice with ductal cell-specific disruption of Pten, with or without activated Kras, we found evidence for a ductal cell origin of IPMNs. We also showed that PTEN loss and activated Kras have synergistic effects in promoting development of IPMN and progression to PDAC.
BACKGROUND & AIMS:Intraductal papillary mucinous neoplasias (IPMNs) are precancerous cystic lesions that can develop into pancreatic ductal adenocarcinomas (PDACs). These large macroscopic lesions are frequently detected during medical imaging, but it is unclear how they form or progress to PDAC. We aimed to identify cells that form IPMNs and mutations that promote IPMN development and progression. METHODS: We generated mice with disruption of Pten specifically in ductal cells (Sox9CreERT2;Ptenflox/flox;R26RYFP or PtenΔDuct/ΔDuct mice) and used PtenΔDuct/+ and Pten+/+ mice as controls. We also generated KrasG12D;PtenΔDuct/ΔDuct and KrasG12D;PtenΔDuct/+ mice. Pancreata were collected when mice were 28 weeks to 14.5 months old and analyzed by histology, immunohistochemistry, and electron microscopy. We performed multiplexed droplet digital polymerase chain reaction to detect spontaneous Kras mutations in PtenΔDuct/ΔDuct mice and study the effects of Ras pathway activation on initiation and progression of IPMNs. We obtained 2 pancreatic sections from a patient with an invasive pancreatobiliary IPMN and analyzed the regions with and without the invasive IPMN (control tissue) by immunohistochemistry. RESULTS:Mice with ductal cell-specific disruption of Pten but not control mice developed sporadic, macroscopic, intraductal papillary lesions with histologic and molecular features of human IPMNs. PtenΔDuct/ΔDuct mice developed IPMNs of several subtypes. In PtenΔDuct/ΔDuct mice, 31.5% of IPMNs became invasive; invasion was associated with spontaneous mutations in Kras. KrasG12D;PtenΔDuct/ΔDuct mice all developed invasive IPMNs within 1 month. In KrasG12D;PtenΔDuct/+ mice, 70% developed IPMN, predominately of the pancreatobiliary subtype, and 63.3% developed PDAC. In all models, IPMNs and PDAC expressed the duct-specific lineage tracing marker yellow fluorescent protein. In immunohistochemical analyses, we found that the invasive humanpancreatobiliary IPMN tissue had lower levels of PTEN and increased levels of phosphorylated (activated) ERK compared with healthy pancreatic tissue. CONCLUSIONS: In analyses of mice with ductal cell-specific disruption of Pten, with or without activated Kras, we found evidence for a ductal cell origin of IPMNs. We also showed that PTEN loss and activated Kras have synergistic effects in promoting development of IPMN and progression to PDAC.
Authors: David A Tuveson; Alice T Shaw; Nicholas A Willis; Daniel P Silver; Erica L Jackson; Sandy Chang; Kim L Mercer; Rebecca Grochow; Hanno Hock; Denise Crowley; Sunil R Hingorani; Tal Zaks; Catrina King; Michael A Jacobetz; Lifu Wang; Roderick T Bronson; Stuart H Orkin; Ronald A DePinho; Tyler Jacks Journal: Cancer Cell Date: 2004-04 Impact factor: 31.743
Authors: Joan Font-Burgada; Shabnam Shalapour; Suvasini Ramaswamy; Brian Hsueh; David Rossell; Atsushi Umemura; Koji Taniguchi; Hayato Nakagawa; Mark A Valasek; Li Ye; Janel L Kopp; Maike Sander; Hannah Carter; Karl Deisseroth; Inder M Verma; Michael Karin Journal: Cell Date: 2015-08-13 Impact factor: 41.582
Authors: N Volkan Adsay; Kambiz Merati; Olca Basturk; Christine Iacobuzio-Donahue; Edi Levi; Jeanette D Cheng; Fazlul H Sarkar; Ralph H Hruban; David S Klimstra Journal: Am J Surg Pathol Date: 2004-07 Impact factor: 6.394
Authors: Wanglong Qiu; Sophia M Tang; Sohyae Lee; Andrew T Turk; Anthony N Sireci; Anne Qiu; Christian Rose; Chuangao Xie; Jan Kitajewski; Hui-Ju Wen; Howard C Crawford; Peter A Sims; Ralph H Hruban; Helen E Remotti; Gloria H Su Journal: Gastroenterology Date: 2015-09-25 Impact factor: 22.682
Authors: Elena Fernandez-Castañer; Maria Vila-Casadesus; Elena Vila-Navarro; Carolina Parra; Juan Jose Lozano; Antoni Castells; Meritxell Gironella Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639